Covered recipient · General Payments record
DAVID ROSMARIN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$267,875.61
215 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $174,215.00 | 69 |
| Consulting Fee | $66,865.75 | 20 |
| Travel and Lodging | $22,050.34 | 70 |
| Food and Beverage | $3,444.52 | 55 |
| Honoraria | $1,300.00 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $74,281.49 | 53 |
| Lilly USA, LLC | $40,700.29 | 40 |
| Amgen Inc. | $29,797.52 | 23 |
| GENZYME CORPORATION | $20,494.50 | 9 |
| ABBVIE INC. | $17,104.13 | 20 |
| Novartis Pharmaceuticals Corporation | $16,996.64 | 11 |
| Eli Lilly and Company | $16,280.01 | 23 |
| Janssen Scientific Affairs, LLC | $13,143.65 | 8 |
| Regeneron Healthcare Solutions, Inc. | $10,672.31 | 8 |
| E.R. Squibb & Sons, L.L.C. | $7,405.04 | 6 |
| Janssen Biotech, Inc. | $7,310.03 | 8 |
| PFIZER INC. | $5,200.00 | 2 |
| Merck Sharp & Dohme LLC | $4,270.00 | 1 |
| UCB, Inc. | $2,360.00 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,860.00 | 1 |
Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID ROSMARIN
NPI 1730353665 · CMS profile ID 1010770
Allopathic & Osteopathic Physicians / Dermatology
INDIANAPOLIS, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1730353665?year=2022&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID ROSMARIN, NPI 1730353665, CMS profile ID 1010770. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730353665?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). DAVID ROSMARIN, NPI 1730353665, CMS profile ID 1010770. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730353665?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- DAVID ROSMARIN, NPI 1730353665, CMS profile ID 1010770, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1730353665?year=2022&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
215 matching records · $267,875.61 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–215 of 215.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $434.25 | 02/17/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891481759 | CMS |
| Incyte Corporation | $3,155.00 | 02/14/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943032999 | CMS |
| Incyte Corporation | $275.00 | 02/14/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943033153 | CMS |
| Amgen Inc. | $1,500.00 | 02/11/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939905395 | CMS |
| Incyte Corporation | $2,800.00 | 02/11/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943032991 | CMS |
| ABBVIE INC. | $1,500.00 | 02/02/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891481755 | CMS |
| Incyte Corporation | $4,200.00 | 01/31/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943032973 | CMS |
| Incyte Corporation | $2,800.00 | 01/31/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943032981 | CMS |
| Incyte Corporation | $433.47 | 01/31/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943033001 | CMS |
| PFIZER INC. | $1,300.00 | 01/28/2022 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949591615 | CMS |
| Incyte Corporation | $133.05 | 01/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943032977 | CMS |
| Janssen Scientific Affairs, LLC | $3,575.00 | 01/20/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887217079 | CMS |
| Incyte Corporation | $107.45 | 01/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943032971 | CMS |
| Incyte Corporation | $709.52 | 01/18/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943032975 | CMS |
| Janssen Scientific Affairs, LLC | $1,430.00 | 01/08/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887217085 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $12,690.00 | 11 |
| PY2025 | Principal investigator | $209,432.13 | 33 |
| PY2024 | Recipient | $1,402.08 | 9 |
| PY2024 | Principal investigator | $169,590.19 | 15 |
| PY2023 | Recipient | $124.95 | 1 |
| PY2023 | Principal investigator | $107,393.84 | 59 |
| PY2022 | Recipient | $299.00 | 1 |
| PY2022 | Principal investigator | $343,154.51 | 104 |
| PY2021 | Recipient | $1,641.00 | 1 |
| PY2021 | Principal investigator | $554,925.42 | 105 |
| PY2020 | Recipient | $4,363.00 | 3 |
| PY2020 | Principal investigator | $679,242.21 | 86 |
| PY2019 | Recipient | $3,146.49 | 3 |
| PY2019 | Principal investigator | $1,247,708.88 | 107 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
44 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,179.12 | 12/31/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY HEALTH CENTER | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202534095 |
| Principal investigator 1 | ABBVIE INC. | $9,060.48 | 12/19/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202531570 |
| Recipient | PFIZER INC. | $1,820.00 | 12/19/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228810955 |
| Recipient | PFIZER INC. | $3,200.00 | 12/19/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228810961 |
| Recipient | PFIZER INC. | $3,200.00 | 12/15/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228810968 |
| Principal investigator 1 | ABBVIE INC. | $2,699.09 | 12/04/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202527990 |
| Principal investigator 1 | Incyte Corporation | $7,461.00 | 11/25/2025 | Non-covered Recipient Entity TRUSTEES OF INDIANA UNIVERSITY | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240604464 |
| Principal investigator 1 | Incyte Corporation | $2,550.00 | 11/19/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1240539022 |
| Principal investigator 1 | PFIZER INC. | $3,350.00 | 11/13/2025 | Non-covered Recipient Entity The Trustees of Indiana University | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228817523 |
| Principal investigator 1 | ABBVIE INC. | $8,116.82 | 11/04/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202521003 |
| Principal investigator 1 | Incyte Corporation | $351.90 | 10/28/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539069 |
| Principal investigator 1 | PFIZER INC. | $25,209.60 | 09/24/2025 | Non-covered Recipient Entity The Trustees of Indiana University | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228836976 |
| Principal investigator 1 | Incyte Corporation | $1,672.20 | 09/11/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539066 |
| Principal investigator 1 | ABBVIE INC. | $800.00 | 08/21/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202505429 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 08/15/2025 | Non-covered Recipient Entity Indiana University Trustees of Indiana University | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | No dispute reported | 06/30/2026 | 1220799868 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,779.15 | 08/14/2025 | Covered Recipient Teaching Hospital TUFTS MEDICAL CENTER | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | No dispute reported | 06/30/2026 | 1184137511 |
| Principal investigator 1 | CSL Behring | $1,000.00 | 07/25/2025 | Non-covered Recipient Entity Indiana University | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252671224 |
| Principal investigator 1 | CSL Behring | $1,900.00 | 07/25/2025 | Non-covered Recipient Entity Indiana University | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252671226 |
| Principal investigator 1 | CSL Behring | $2,850.00 | 07/25/2025 | Non-covered Recipient Entity Indiana University | A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects | No dispute reported | 06/30/2026 | 1252671228 |
| Principal investigator 1 | Incyte Corporation | $351.90 | 07/22/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539044 |
| Principal investigator 1 | AstraZeneca UK Limited | $36,390.24 | 07/18/2025 | Non-covered Recipient Entity TRUSTEES OF INDIANA UNIVERSITY | A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or Intolerant to Antimalarial Therapy | No dispute reported | 06/30/2026 | 1185544707 |
| Principal investigator 1 | Incyte Corporation | $16,800.00 | 07/10/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539040 |
| Principal investigator 1 | Incyte Corporation | $3,400.00 | 07/10/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539047 |
| Principal investigator 1 | Incyte Corporation | $4,600.00 | 07/10/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539051 |
| Principal investigator 1 | Incyte Corporation | $144.00 | 07/10/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539055 |
| Principal investigator 1 | Incyte Corporation | $7,600.00 | 07/10/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539059 |
| Principal investigator 1 | Incyte Corporation | $12,471.68 | 07/10/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539063 |
| Principal investigator 1 | ABBVIE INC. | $8,115.00 | 07/02/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202496551 |
| Recipient | PFIZER INC. | $940.00 | 06/28/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228839337 |
| Principal investigator 1 | ABBVIE INC. | $8,944.00 | 06/25/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202492895 |
| Principal investigator 1 | Incyte Corporation | $2,601.90 | 06/19/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539035 |
| Principal investigator 1 | PFIZER INC. | $915.57 | 06/09/2025 | Non-covered Recipient Entity Indiana University Health Univ | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228814645 |
| Recipient | PFIZER INC. | $940.00 | 06/07/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838958 |
| Recipient | PFIZER INC. | $940.00 | 06/07/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228839041 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 06/01/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539073 |
| Recipient | PFIZER INC. | $330.00 | 05/15/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228839176 |
| Recipient | PFIZER INC. | $330.00 | 05/06/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838210 |
| Recipient | PFIZER INC. | $330.00 | 05/06/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838558 |
| Recipient | PFIZER INC. | $330.00 | 05/06/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228839019 |
| Recipient | PFIZER INC. | $330.00 | 05/06/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228839477 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 05/03/2025 | Non-covered Recipient Entity The Trustees of Indiana University | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228857147 |
| Principal investigator 1 | Incyte Corporation | $351.90 | 05/02/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539030 |
| Principal investigator 1 | Incyte Corporation | $10,422.90 | 04/10/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539026 |
| Principal investigator 1 | ABBVIE INC. | $18,298.68 | 02/03/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202443606 |